SILVER SPRING, Md., May 31, 2016 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that the Chief Executive Officer of PharmaCyte will be a featured presenter at the 5th Annual Marcum MicroCap Conference on Thursday, June 2, 2016, in New York City at the Grand Hyatt Hotel. The presentation is scheduled to begin at 9:30 a.m. EDT and will be available via a live webcast. To access the webcast go to http://wsw.com/webcast/marcum4/pmcb.
PharmaCyte’s Chief Executive Officer, Kenneth L. Waggoner, said of the opportunity to speak at the Marcum MicroCap Conference, “We have a very busy June ahead of us, and it all begins in New York at Marcum. I couldn’t be more excited to present PharmaCyte’s remarkable story to a captive audience at this conference. We expect that many of our shareholders will listen in as well. From New York we head to Chicago to participate in ASCO 2016, the annual meeting of the American Society of Clinical Oncology (ASCO) and then to San Francisco to attend BIO 2016. So in addition to all of the work in which we are involved in getting our pancreatic cancer therapy into a Phase 2b clinical trial, we have some exceptional opportunities to tell what is truly an amazing story about our therapies that use PharmaCyte’s signature live-cell encapsulation technology, Cell-in-a-Box®.”
The annual Marcum MicroCap Conference is a signature showcase for superior quality, lesser known public companies with less than $500 million in market capitalization. The Marcum MicroCap Conference is dedicated to providing a forum where these companies can network with the investment community. The conference features presentations by CEOs and CFOs from seven principal industry sectors, expert panels moderated by industry leaders and the opportunity to meet with management of presenting companies on a one-on-one basis. The event attracts fund managers and high net worth investors who focus on small cap equities. Over 2,000 participants of the microcap market participated in last year’s conference
About PharmaCyte Biotech
PharmaCyte Biotech is a clinical stage biotechnology company developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as “Cell-in-a-Box®.” This technology will be used as a platform upon which treatments for several types of cancer and diabetes are being developed. PharmaCyte’s treatment for cancer involves encapsulating genetically modified live cells that convert an inactive chemotherapy drug into its active or “cancer-killing” form. These encapsulated live cells are placed as close to a cancerous tumor as possible. Once implanted in a patient, a chemotherapy drug which needs to be activated in the body (ifosfamide) is then given intravenously at one-third the normal dose. The ifosfamide is carried by the circulatory system to where the encapsulated cells have been placed. When the ifosfamide, which is normally activated in the liver, comes in contact with the encapsulated live cells, activation of the chemotherapy drug takes place at the source of the cancer without any side effects from the chemotherapy. This “targeted chemotherapy” has proven remarkably effective and safe to use in past clinical trials.
In addition to developing a novel treatment for cancer, PharmaCyte is developing a treatment for Type 1 diabetes and insulin-dependent Type 2 diabetes. PharmaCyte plans to encapsulate a human cell line that has been genetically engineered to produce, store and release insulin in response to the levels of blood sugar in the human body. The encapsulation will be done using the Cell-in-a-Box® technology.
About Marcum LLP
Marcum LLP is one of the largest independent public accounting and advisory services firms in the nation, with offices in major business markets throughout the U.S., Grand Cayman and China. Headquartered in New York City, Marcum provides a full spectrum of traditional tax, accounting and assurance services; advisory, valuation and litigation support; and an extensive range of specialty and niche industry practices. Marcum serves both privately held and publicly traded companies, as well as high net worth individuals, private equity and hedge funds, with a focus on middle-market companies and closely held family businesses. In 2015, Marcum’s SEC Services Practice group led all non “Big Four” accounting firms in the performance of audits in connection with Initial Public Offerings (“IPOs”). Marcum is a member of the Marcum Group, an organization providing a comprehensive array of professional services. For more information, visit www.marcumllp.com.
Safe Harbor
This press release may contain forward-looking statements regarding PharmaCyte Biotech and its future events and results that involve inherent risks and uncertainties. The words “anticipate”, “believe”, “estimate”, “expect”, “intend”, “plan” and similar expressions, as they relate to PharmaCyte or its management, are intended to identify forward-looking statements. Important factors, many of which are beyond the control of PharmaCyte, could cause actual results to differ materially from those set forth in the forward-looking statements. They include PharmaCyte’s ability to continue as a going concern, delays or unsuccessful results in preclinical and clinical trials, flaws or defects regarding its product candidates, changes in relevant legislation or regulatory requirements, uncertainty of protection of PharmaCyte’s intellectual property and PharmaCyte’s continued ability to raise capital. PharmaCyte does not assume any obligation to update any of these forward-looking statements.
More information about PharmaCyte Biotech can be found at www.PharmaCyte.com. It can also be obtained by contacting Investor Relations.
Investor Relations: PharmaCyte Biotech, Inc. Investor Relations Department Telephone: 917.595.2856 Email: [email protected]
Source: PharmaCyte Biotech, Inc.
